# A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

> **NCT02452268** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 83 (actual)

## Conditions studied

- Metastatic and Advanced Solid Tumors

## Interventions

- **DRUG:** NIZ985
- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT02452268
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-08
- **Primary completion:** 2022-03-07
- **Final completion:** 2022-03-07
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** business decision
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452268, "A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02452268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*